Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs NVR Inc. Common Stock (NVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs NVR Inc. Common Stock — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.71 (market cap $1.66B), while NVR Inc. Common Stock trades at $5,750 (market cap $15.45B). The key difference: NVR Inc. Common Stock is far larger — about 9.3× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, NVR Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 6 Days and NVR Inc. Common Stock for 0 Days on average.
| NUVB | NVR | |
|---|---|---|
Market Cap | $1.66B | $15.45B |
Volume | 7,608,075 | 53,419 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.54 | $8.10K |
52-Week Low | $3.41 | $5.56K |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.25B | $15.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →
